Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
April 28, 2022 at 04:47 am EDT
Share
Tianjin Chase Sun Pharmaceutical Co.,Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 1,732.43 million compared to CNY 1,638.99 million a year ago. Revenue was CNY 1,732.43 million compared to CNY 1,638.99 million a year ago. Net income was CNY 238.24 million compared to CNY 193.16 million a year ago. Basic earnings per share from continuing operations was CNY 0.08 compared to CNY 0.06 a year ago. Diluted earnings per share from continuing operations was CNY 0.08 compared to CNY 0.06 a year ago.
Tianjin Chase Sun Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Company's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The Company also provides medical apparatus and instrument. The Company distributes its products in domestic market and to overseas markets.